Strategic partnership Kryptos Biotechnologies recently partnered with Osang Healthcare for manufacturing, distribution, and financing, signaling interest from established players and potential channel opportunities to scale sales of their 20-minute PCR-based point-of-care system.

Clinical efficiency Their technology enables rapid sample-to-answer diagnostics in 20 minutes with lab-level accuracy, presenting a strong value proposition for hospitals, urgent care centers, and mobile clinics seeking faster treatment decisions and improved patient throughput.

Early-stage traction With pre-Series A financing and revenue in the low single-digit millions, there is growing investor and market validation, suggesting opportunities for targeted outreach to strategic investors, contract manufacturers, and early adopter health systems.

Niche leadership Focusing on single-cell level cancer diagnostics and photothermal heating for device miniaturization positions Kryptos to engage oncology centers, translational research labs, and biotech distributors seeking innovative molecular diagnostic solutions.

SF Bay advantage Based in the San Francisco Bay Area with a lean team, Kryptos can leverage proximity to biotech clusters for pilot deployments, NI/CI partnerships, and co-development deals with nearby health systems and contract manufacturers.